Cathy Tie launches VC‑backed embryo‑editing startup
SkimNews Take
The commercialization of embryo editing, even with a focus on disease prevention, implicitly shifts the societal debate from hypothetical ethical concerns to the practicalities of regulatory oversight and public acceptance.
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Cathy Tie performed at Carnegie Hall on her 30th birthday, playing Saint‑Saëns Piano Concerto No. 2 on a Steinway grand piano.
- Cathy Tie has launched three biotech companies since early 2025, lived in Los Angeles, Toronto, and New York, and was banned from China while en route to Beijing.
- Cathy Tie married former He Jiankui, the biophysicist imprisoned for creating gene‑edited babies, and they separated three months after their wedding.
- Cathy Tie announced a New York‑based startup to edit embryos for disease prevention (cystic fibrosis, Huntington’s disease, hereditary cancers) using CRISPR, pledging regulator‑approved, transparent, VC‑backed operations.
- Cathy Tie notes that CRISPR‑Cas9, invented in 2012, enables precise DNA edits of germline cells (eggs, sperm, early embryos) with relatively simple steps.
Why it matters: Patients with hereditary diseases stand to benefit, while investors see Tie’s third biotech venture, prompting regulators to confront a new wave of commercial embryo editing and ethical oversight.
Ask SkimNews
